Cabozantinib in combination with atezolizumab as a first-line therapy in patients with radioiodinerefractory differentiated thyroid cancer: Results from cohort 18 of the phase 1b COSMIC-21 study.
Document Type
Presentation
Publication Date
10-19-2022
Keywords
oregon; chiles
Area of Special Interest
Cancer
Specialty/Research Institute
Oncology
Specialty/Research Institute
Earle A. Chiles Research Institute
Comments
Presented at the American Thyroid Association Conference 2022 October 19-23; Montreal, Quebec Canada.